HealthcareNYSE
Institutional-grade research for retail investors
SEC EDGAR: CIK 1812173RBOT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 37 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RBOT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vicarious Surgical Inc. (RBOT), a Healthcare sector company. RBOT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 37 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q4 2025), Vicarious Surgical Inc. reports net income of $-10.5M, free cash flow of $-9.3M. Top institutional holders of RBOT by reported 13-F value include Rockefeller Capital Management L.P., Hughes Financial Services,, Daytona Street Capital, based on the most recent SEC filings. RBOT trades on the NYSE exchange and files with the SEC under CIK 1812173. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vicarious Surgical Inc. directly from SEC EDGAR.

Net Income

Q4 2025

$-10.5M

Free Cash Flow

Q4 2025

$-9.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+20.6% YoY
$-50.2MFY 2025
FY22 $5.2MFY23 $-71.1MFY24 $-63.2MFY25 $-50.2M

Operating Income

+24.8% YoY
$-50.0MFY 2025
FY22 $-80.1MFY23 $-80.7MFY24 $-66.6MFY25 $-50.0M

EPS (Diluted)

FY 2025
FY22 $0.04FY23 $-0.49FY24 FY25

Total Assets

-71.1% YoY
$19.6MFY 2025
FY22 $140.3MFY23 $119.9MFY24 $67.7MFY25 $19.6M

Total Debt

FY 2025
FY22 FY23 $2.0MFY24 FY25

Op. Cash Flow

+9.8% YoY
$-45.1MFY 2025
FY22 $-61.2MFY23 $-62.3MFY24 $-50.0MFY25 $-45.1M

AI Insight: RBOT Ratio Trends

Limited financial data available, but visible metrics show severely deteriorating returns with ROE declining from -81.0% in Q1 2024 to -180.7% in Q1 2025.

ROE deteriorated from -81.0% in Q1 2024 to -180.7% in Q1 2025, indicating worsening shareholder returns.

ROA declined from -64.6% in Q1 2024 to -84.8% in Q3 2024 before data gaps emerged.

Extensive data gaps across most recent quarters suggest potential reporting issues or business disruption.

All available return metrics remain deeply negative, indicating ongoing operational challenges for this healthcare company.

Get alerted when RBOT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vicarious Surgical Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put RBOT on your watchlist

Track score changes the day Vicarious Surgical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is RBOT a good stock to buy?

13F Pro's AI-powered analysis of Vicarious Surgical Inc. (RBOT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RBOT are available on the RBOT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RBOT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RBOT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vicarious Surgical Inc.'s investment landscape.